HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab
- 15 May 2012
- journal article
- clinical trial
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 72 (4), 560-565
- https://doi.org/10.1136/annrheumdis-2011-201228
Abstract
Objective An atherogenic lipid profile is an established risk factor for cardiovascular (CV) diseases. Interestingly, high inflammatory states as present in rheumatoid arthritis (RA) are associated with unfavourable lipid profile. Data about effects of novel immunomodulating agents as rituximab (RTX) on lipid profile are limited. Therefore, changes in lipids in RTX treated RA patients were evaluated. Methods In 49 consecutive RTX treated RA patients, serum and EDTA plasma samples were collected at baseline, 1, 3 and 6 months. In these samples, lipid and levels were assessed to determine changes in time. Surface-enhanced laser desorption/ionisation time-of-flight (SELDI-TOF) MS analysis was performed in six good and six non-responding RA patients to study functional high density lipoprotein (HDL) protein composition changes in time. Results In the total group (n=49), the atherogenic index decreased from 4.3 to 3.9 (∼9%) after 6 months. Testing for effect modification revealed a difference in the effect on lipid levels between responders and non-responders upon RTX (pConclusion This study indicates beneficial effects on cholesterol profile upon RTX treatment along with improvement of disease activity. Proteomic analysis of the HDL particle reveals composition changes from proatherogenic to a less proatherogenic composition during 6 months RTX treatment. Whether these HDL particle alterations during immunotherapies result in a lower CV event rate remains to be established.Keywords
This publication has 40 references indexed in Scilit:
- Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2012
- Abnormal function of high‐density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritisArthritis & Rheumatism, 2009
- The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trialsBMJ, 2009
- Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2008
- Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2007
- Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2006
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- The mortality of rheumatoid arthritisArthritis & Rheumatism, 1994
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988